Improving parenchymal phase imaging of the pancreas with multidetector CT using experience from dynamic contrast enhanced MR studies.

ISRCTN	ISRCTN84780767
DOI	https://doi.org/10.1186/ISRCTN84780767
Protocol serial number	N0258161818
Sponsor	Record Provided by the NHSTCT Register - 2006 Update - Department of Health
Funders	The Royal Marsden NHS Foundation Trust, NHS R&D Support Funding

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Dr Nandita De Souza
Scientific

Clinical Magnetic Resonance
The Royal Marsden NHS Foundation Trust
Downs Road
Sutton
SM2 5PT
United Kingdom

Phone	+44 (0)20 8661 3289
Email	nandita.desouza@icr.ac.uk

Primary study design	Interventional
Study design	Randomised controlled trial
Secondary study design	Randomised controlled trial
Study type	Participant information sheet
Scientific title
Study objectives	To improve the diagnosis of pancreatic cancer by exploiting technology available on newer CT scanners to improve the enhancement of normal pancreatic tissue. As of 15/05/2012, the anticipated end date for this trial has been updated from 18/04/2006 to 30/06/2006.
Ethics approval(s)	Not provided at time of registration
Health condition(s) or problem(s) studied	Cancer: Pancreatic
Intervention	Randomised test intervention vs standardised intervention, non-blinded (Phase III)
Intervention type	Other
Primary outcome measure(s)	1. Absolute value of the Hounsfield attenuation in normal pancreatic tissue at pancreatic parenchymal phase. 2. Clinical radiologist's impression on the utility/benefit of mucosal enhancement of adjacent duodenum in aiding local staging.
Key secondary outcome measure(s)	Not provided at time of registration
Completion date	30/06/2006
Reason abandoned (if study stopped)	Lack of staff/facilities/resources

Participant type(s)	Patient
Age group	Adult
Lower age limit	18 Years
Sex	All
Target sample size at registration	60
Key inclusion criteria	1. Age over 18 - pancreatic adenocarcinoma is unusual below this age and children are more sensitive to additional ionising radiation than adults 2. Stage III ovarian cancer or colorectal cancer 3. Routine attendance for contrast enhanced abdominal CT - no patients not otherwise having CT and contrast will be approached.
Key exclusion criteria	1. Severe local disease affecting pancreatic aorta/branches. This may introduce delays to the arrival of contrast due to compromise of arteries (SMA/Coeliac axis) 2. Major atherosclerotic disease of SMA/Coeliac axis - again, to avoid significant delay in contrast path distal to pancreatic aorta 3. Significant pancreatic resection - absence of normal pancreatic tissue will preclude our numerical assessment of enhancement 4. Pre-existing pancreatic disease - cancer or pancreatitis.
Date of first enrolment	19/09/2005
Date of final enrolment	30/06/2006

Clinical Magnetic Resonance

Sutton
SM2 5PT
United Kingdom

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
IPD sharing plan

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes